Atopic dermatitis is a clinically diagnosed, severity-graded spectrum — and only the ~40% with moderate-to-severe disease enter the biologic- and JAK-eligible commercial segment.
Atopic dermatitis (AD) is a chronic, relapsing, type 2 inflammatory skin disease driven by epidermal barrier dysfunction (including filaggrin loss-of-function mutations) and IL-4, IL-13, and IL-31 cytokine signalling. It affects an estimated 16.5 million US adults (approximately 7% adult prevalence) and more than 9.6 million US children (10–13% pediatric prevalence). Diagnosis is clinical (there is no confirmatory laboratory biomarker), anchored on Hanifin-Rajka or UK Working Party criteria, with severity graded by EASI, IGA, and SCORAD. Endotype heterogeneity across age, ethnicity, and filaggrin status increasingly informs targeted therapy selection.
Severity distribution is the commercial pivot. Most patients have mild disease managed with emollients and topicals, while approximately 40% of adults (roughly 6.6 million) carry moderate-to-severe disease inadequately controlled by topical therapy, the population eligible for systemic biologics and oral JAK inhibitors. AD is typically the first manifestation of the atopic march, preceding food allergy, asthma, and allergic rhinitis in a subset of children, though recent evidence shows most atopic comorbidities do not follow a strict temporal sequence. This moderate-to-severe, topical-refractory segment is where dupilumab's ~70% biologic share and the JAK step-edit landscape play out.
US atopic dermatitis by segment — prevalence, severity, and commercial implication
| Segment | Prevalence (US est.) | Defining Feature | Key Burden | Treatment Implication |
|---|---|---|---|---|
| Mild AD (adult + pediatric) | ~60–70% of AD | Localized eczema; low EASI/IGA | Itch, sleep disruption, recurrent flares | Emollients + topical corticosteroids/calcineurin inhibitors; rarely systemic |
| Moderate-to-severe adult AD | ~6.6M adults (~40% of adult AD) | Widespread lesions; IGA 3–4; topical-refractory | Chronic itch, sleep loss, skin infection, mental-health burden | Biologic (dupilumab / IL-13) first-line systemic; JAK if biologic-refractory |
| Pediatric AD | ~9.6M children (10–13%) | Early onset; flexural eczema | Itch, sleep/school impact; atopic march risk | Topicals; dupilumab approved from 6 months for moderate-to-severe |
| Severe / topical-refractory AD | ~2.8–15.6% of adult AD is severe | IGA 4; high EASI; systemic-dependent | Highest QoL and comorbidity burden | Systemic biologic or JAK; specialist-managed |
Sources: Migliavaca CB et al. Dermatitis 2024 systematic review/meta-analysis (PMID 39134072); Barbarot S et al. Allergy 2018 (PMID 29319189); Czarnowicki T et al. J Allergy Clin Immunol 2019 endotypes (PMID 30612663); Ramírez-Marín HA, Silverberg JI. Pediatr Dermatol 2022 (PMID 35297082); American Academy of Dermatology AD prevalence estimates; CDC/NHANES.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- US adult and pediatric AD prevalence with source triangulation
- severity distribution (mild/moderate/severe)
- moderate-to-severe pool sizing
- topical-refractory eligible segment for systemic therapy
Delivers
- Clinical diagnostic criteria (Hanifin-Rajka, UK Working Party)
- severity instruments (EASI, IGA, SCORAD)
- dermatologist vs primary-care diagnosis pathways
- gaps in moderate-to-severe recognition
Delivers
- Atopic march sequence and comorbidity co-occurrence
- AD endotypes by age, ethnicity, and filaggrin status
- type 2 inflammation biomarkers
- implications for pediatric-to-adult treatment continuity
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Epidermal barrier dysfunction, including filaggrin loss-of-function mutations, combines with IL-4, IL-13 and IL-31 cytokine signalling to drive chronic type 2 inflammation
- Why AD is a chronic, relapsing disease rather than a single acute event, with no confirmatory laboratory biomarker for diagnosis
- An estimated 16.5 million US adults (about 7% prevalence) and more than 9.6 million US children (10–13% prevalence) have atopic dermatitis
- Pediatric prevalence roughly doubles adult prevalence, reflecting AD's typical onset as the first manifestation of the atopic march
- Roughly 40% of adults, about 6.6 million people, carry moderate-to-severe disease inadequately controlled by topical therapy, the segment eligible for systemic biologics and JAK inhibitors
- Dupilumab holds roughly 70% biologic share within this moderate-to-severe, topical-refractory segment
- Diagnosis is clinical, anchored on Hanifin-Rajka or UK Working Party criteria, since there is no confirmatory laboratory biomarker
- Severity is graded using EASI, IGA and SCORAD instruments, the tools that determine biologic and JAK eligibility
- AD is typically the first manifestation of the atopic march, preceding food allergy, asthma and allergic rhinitis in a subset of children
- Recent evidence shows most atopic comorbidities do not follow a strict temporal sequence, complicating the classic atopic-march narrative
- Endotype heterogeneity across age, ethnicity and filaggrin status increasingly informs which patients respond best to which targeted therapy
- Why filaggrin status and cytokine-signalling profile are becoming segmentation variables alongside classic severity scores like EASI and IGA
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Atopic dermatitis disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and national survey data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.
Key sources: Migliavaca CB et al. Dermatitis 2024 (PMID 39134072); Barbarot S et al. Allergy 2018 (PMID 29319189); Czarnowicki T et al. J Allergy Clin Immunol 2019 (PMID 30612663); Ramírez-Marín HA, Silverberg JI. Pediatr Dermatol 2022 (PMID 35297082); American Academy of Dermatology and CDC/NHANES prevalence data.
- Adult and pediatric prevalence verified against peer-reviewed meta-analysis (Migliavaca et al. Dermatitis 2024) and Barbarot et al. Allergy 2018
- Severity distribution (proportion moderate-to-severe and severe) verified against published epidemiology (Migliavaca et al. 2024; Barbarot et al. 2018)
- Diagnostic criteria and endotype characterisation verified against Czarnowicki et al. J Allergy Clin Immunol 2019
- Atopic march and pediatric-adult differences verified against Ramírez-Marín & Silverberg, Pediatr Dermatol 2022
Frequently asked questions
Commission this assessment
AXLRx US Atopic Dermatitis Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US AD patient population and its moderate-to-severe segment. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.